<DOC>
	<DOCNO>NCT01893242</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate potential aleglitazar reduce risk end stage renal disease cardiovascular mortality patient type 2 diabetes mellitus chronic kidney disease . Patients randomize receive oral daily dos aleglitazar match placebo . The anticipated time study treatment approximately 3 year .</brief_summary>
	<brief_title>A Study Alegitazar Patients With Type 2 Diabetes And Chronic Kidney Disease ( Alerenal Study )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Adult patient &gt; = 18 year age screen Diagnosis diabetes mellitus Type 2 Glycosylated hemoglobin A1C ( HbA1C ) &lt; 10 % screening Estimated glomerular filtration rate ( eGFR ) &gt; =30 &lt; 60 mL/min/1.73 m2 Urinary albumintocreatinine ratio ( UACR ) &gt; =500 &lt; 5000 mg/g Treatment either angiotensin convert enzyme inhibitor angiotensin II receptor blocker least three month prior screen Women childbearing potential use highly effective birth control method must willing use method contraception entire course study Treatment PPARgamma agonist and/or PPARalpha agonist last 12 week screen Prior intolerance TDZ fibrate Previous participation trial aleglitazar Diagnosis history type diabetes Diagnosis history acute metabolic diabetic complication within past 6 month Known primary glomerulonephritis , secondary glomerulonephritis diabetic nephropathy polycystic kidney disease Diagnosed acute kidney injury dialysis within 12 week prior screen Poorly control hypertension ( systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 100 mmHg baseline ) Known secondary hypertension due renal artery stenosis , primary aldosteronism , pheochromocytoma History myocardial infarction stroke past 12 week prior screen Symptomatic congestive heart failure NYHA class IIIV baseline heart failure lead hospitalization within 12 month prior screen Diagnosed and/or treat malignancy ( except treat case basal cell skin cancer , situ carcinoma cervix , situ prostate cancer ) within past 5 year Inadequate liver hematological function Chronic treatment immunosuppressive therapy Women pregnant , intend become pregnant study period , currently lactate female , woman childbearing potential use highly effective birth control method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>